GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
GlobalRPh source record

Dalfampridine (Ampyra)

Read renal action and limits
Local official-label summarySource retrieved 2026-09-05See the evidence for this drug3 sources available - open source summaries, references and comparisons

Ampyra

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist

Choose a source to read (3)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
Ampyra - product and source limitations

Determine CrCl before treatment and at least annually. Swallow tablets whole. A lower-strength renal regimen is unavailable.

Before applying: Apply only to the stated formulation, indication and renal population.

Also check: Ampyra - product and source limitations

Official source

Ampyra - labeled renal guidance

Renal action and limits

Dalfampridine (Ampyra), oral extended-release tablets for adult MS
Cockcroft-Gault creatinine clearance, mL/min

Action or finding
At CrCl <=50 mL/min, Ampyra is contraindicated. At 51-80, weigh walking benefit against the risk of seizures from increased exposure.
Limits and monitoring
Determine CrCl before treatment and at least annually. Swallow tablets whole. A lower-strength renal regimen is unavailable.
Before use
Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 22, effective 2026-01-16; posted Jan 23, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.

Choose a product and source GlobalRPh RX passage All evidence
Product / population
Dalfampridine (Ampyra), oral extended-release tablets for adult MS
Renal measure
Cockcroft-Gault creatinine clearance, mL/min
Source revision
DailyMed SPL version 22, effective 2026-01-16; posted Jan 23, 2026
Retrieved
2026-11-07 (not the revision date)
Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.

Renal guidance: 2.3, 2.4, 4 and 8.6

At CrCl <=50 mL/min, Ampyra is contraindicated. At 51-80, weigh walking benefit against the risk of seizures from increased exposure. Determine CrCl before treatment and at least annually. Swallow tablets whole. A lower-strength renal regimen is unavailable.

Source revision: DailyMed SPL version 22, effective 2026-01-16; posted Jan 23, 2026 | Retrieved: 2026-11-07. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=550eb76a-e4a6-4fa1-ad65-c0fd8b0ce783

Scope: Selected renal passages reviewed; independent clinician adjudication pending. GlobalRPh v7.4.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

Ampyra - labeled renal guidance

Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.

Dalfampridine (Ampyra), oral extended-release tablets for adult MS

Renal method: Cockcroft-Gault creatinine clearance, mL/min
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference
GlobalRPh RX List

Ampyra - selected RX renal passage

Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.

Dalfampridine (Ampyra), oral extended-release tablets for adult MS

Renal method: Use the renal measure explicitly present in the RX passage.
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Ampyra - product and source limitations

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

Source scope / renal recommendation differences

Ampyra - product and source limitations

Determine CrCl before treatment and at least annually. Swallow tablets whole. A lower-strength renal regimen is unavailable.

How to use this: Apply only to the stated formulation, indication and renal population.

Ampyra - labeled renal guidanceAmpyra - selected RX renal passage

Selected renal passages reviewed; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeAmpyra - labeled renal guidanceAmpyra - selected RX renal passage
Choose two source checkboxes below.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Original GlobalRPh protocol

Clinical facts and comments transcribed into a structured reading format. Read the original source for its complete context: https://globalrph.com/renal/dalfampridine-ampyra/

Usual Dosing (Adults)

AMPYRA is a potassium-channel blocker for improvement of walking in multiple sclerosis, demonstrated by increased walking speed. Maximum 10 mg twice daily approximately 12 hours apart, with or without food. Do not take extra/double doses for a missed dose. Higher doses showed no additional benefit and more adverse events including seizures. Take tablets whole; do not divide, crush, chew or dissolve. Strength: 10 mg tablets.

GRPH-dalfampridine-ampyra-01 · Source section: Usual Dosing (Adults)Renal section finder

Renal Dosing

Contraindicated in moderate or severe renal impairment. In mild impairment (CrCl 51 to 80 mL/min), seizure risk is unknown, but exposure may approach that at 15 mg twice daily, which may increase seizures. Know estimated CrCl before starting treatment.

GRPH-dalfampridine-ampyra-02 · Source section: Renal DosingRenal section finder

Hemodialysis

Contraindicated. Do not use.

GRPH-dalfampridine-ampyra-03 · Source section: HemodialysisRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Ampyra - labeled renal guidance

Open original reference

Open / share this exact local source

DailyMed / product prescribing information · Dalfampridine (Ampyra), oral extended-release tablets for adult MS

Renal method: Cockcroft-Gault creatinine clearance, mL/min
Source date: DailyMed SPL version 22, effective 2026-01-16; posted Jan 23, 2026
Retrieved: 2026-11-07

Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: 2.3, 2.4, 4 and 8.6

At CrCl <=50 mL/min, Ampyra is contraindicated. At 51-80, weigh walking benefit against the risk of seizures from increased exposure. Determine CrCl before treatment and at least annually. Swallow tablets whole. A lower-strength renal regimen is unavailable.

RDM73-ampyra-official-1 · Source locator: Renal guidance: 2.3, 2.4, 4 and 8.6

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=550eb76a-e4a6-4fa1-ad65-c0fd8b0ce783
Retrieved
2026-11-07
Renal-function method
Cockcroft-Gault creatinine clearance, mL/min
Source date/version
DailyMed SPL version 22, effective 2026-01-16; posted Jan 23, 2026
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
db358b3b2d1640addbe3f867e451e6e285a263d4d162ada5c7305cc3de5a857f
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

Ampyra - selected RX renal passage

Open original reference

Open / share this exact local source

GlobalRPh RX List / product-label mirror · Dalfampridine (Ampyra), oral extended-release tablets for adult MS

Renal method: Use the renal measure explicitly present in the RX passage.
Source date: Mirror revision not established in the reviewed passage.
Retrieved: 2026-11-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.

Selected renal passages reviewed; independent clinician adjudication pending.

RX List: selected renal passage

The mirror identifies the seizure risk at CrCl 51-80 and the contraindication at or below 50 mL/min.

RDM73-ampyra-rxlist-1 · Source locator: RX List: selected renal passage

Source-specific limits

This mirror and the underlying product label share a source family.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/ampyra-drug/
Retrieved
2026-11-07
Renal-function method
Use the renal measure explicitly present in the RX passage.
Source date/version
Mirror revision not established in the reviewed passage.
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
bea46c56a04ff0ad5a76beec3e2c2be9603b46cc3b954136020c1fd8a5762592

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/renal/dalfampridine-ampyra/
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
globalrph individual
Local text SHA-256
c72ec21e48b5651e90b2394bf28ce8ace5dac6f89bde3bb677bcf14714023979
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.

Read the full coverage report
Top